Response  by Putnam, S.D. et al.
closed population over a period of 3–5 months might have
exerted a selection pressure over the circulating strains.
In the discussion section, ‘access’ is probably misprinted for
‘assess’.
Comments on the rather low overall prevalence of
S. pyogenes, and on the extraordinarily low one of S. pneumoniae
– which cast doubts on the sensitivity of the isolation pro-
cedures – confusedly suggest, but do not admit, that the
statistical power of the study was simply not adequate to draw
conclusions.
Doubts also arise about the ‘point prevalence snapshots’, as
the periods of training did not start and finish at single time
points, given that the study was conducted ‘between November
1994 and March 1995’; the actual date of the isolations should
have been considered as a covariate.
The statement that the study was conducted in accordance
with official guidelines is a poor substitute for the one usually
required for clinical trials, and we remain with the disturbing
doubt: has each study subject given a written and truly informed
consent?
In conclusion, we much regret to see the official journal of
the European Society of Clinical Microbiology and Infection
accept as an Original Article a paper which is an untimely and
incompetent manipulation of data already published. Needless
to say, we would never advocate the mass use of azythromycin
(or any other drug) to reduce streptococcal colonization in
healthy adults.
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Response
We appreciate the authors’ criticisms of our paper [1], but we
wish to clarify some of their misunderstandings.
Our paper’s [2] focus was rather simple. Using data from a
previously published clinical trial [3], we sought to assess
changes in antimicrobial susceptibility levels of two common
respiratory pathogens (Streptococcus pyogenes and S. pneumoniae)
among US military personnel enrolled in a respiratory disease
chemoprophylaxis trial. Our findings, based upon limited data,
indicated that there was little or no change in the minimum
inhibitory concentrations (MICs) before and after the admin-
istration of the chemoprophylactic drugs.
We agree with Urbano and Urbano that using a single 1.2
million unit injection of benzathine penicillin G (BPG) injec-
tion is limited in its antimicrobial scope. We also recognize that
the prophylactic effect of BPG against S. pyogenes is expected to
protect an individual for only 2–4 weeks [4]. However, for more
than 40 years, the US Department of Defense has successfully
used mass BPG prophylaxis to prevent and control respiratory
infection epidemics among military trainees [5–9]. This protec-
tion has been broad, frequently exceeding the magnitude of that
which would be explained by the reduction of streptococcal
infections alone [10]. The protection has also been prolonged,
especially among US Army trainees, where a single dose of BPG
will often protect a cohort for up to 8 weeks [10]. Although not
well understood, the broad and persistent control is thought to
be due to the impact mass BPG prophylaxis has on endemic
respiratory pathogens in a training cohort as a whole. Such
cohorts experience little mixing with other cohorts and benefit
from a mass BPG influenced ‘herd protection’.
As several ‘outbreaks’ of respiratory disease had occurred
among US Marine trainees in Southern California in the late
1980s and early 1990s, the value of BPG interventions was
questionable, considering the mixed etiology of infecting agents
[11–13]. There was also concern that BGP prophylaxis might
eventually select for penicillin-resistant/tolerant S. pyogenes
strains and the US Department of Defense would be wise to
identify alternative therapies. In contrast to Urbano and
Urbano’s comments, we believe the literature suggests that
the threat of selecting for penicillin tolerance/resistance to be
very real [14–16]. We were seeking an alternative antibiotic
intervention with broad impact, for use in fast-moving respira-
tory epidemics. The aim of the original study [3] was to
compare the efficacy of azithromycin with the then routine
outbreak intervention of a single injection of BPG [9]. We
compared the interventions for their protection against a
number of respiratory pathogens.
We agree that the isolation procedure (throat swabs) for the
recovery of both strains was not the optimal method and
may have underestimated the true prevalence of both species
among our trainees. However, the same method was used for
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the pre- and post collection in all three treatment groups, and it
is unlikely that a reduction in detection would have markedly
changed our findings.
Finally, we agree with Urbano and Urbano that the statistical
methods and analysis used in this study were not optimal, but
they were adequate for the generalized MIC comparison
between groups. Cross-sectional samplings were used under
a simple pre- and post-treatment design and the results, with
limited statistical power due to low prevalences, should be
viewed as hypothesis-generating. We also agree that further
chemoprophylaxis studies are merited to fully satisfy our obser-
vations that chemoprophylaxis with azithromycin did not
appear to induce antibiotic resistance in either S. pneumoniae
or S. pyogenes.
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